Risk Factors for Ambulatory Urinary Tract Infections Caused by High-MIC Fluoroquinolone-susceptible Escherichia Coli in Women: Results from a Large Case-control Study

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Jan 30

PMID 25630645

Citations 7

Authors

Pinyo Rattanaumpawan

Irving Nachamkin

Warren B Bilker

Jason A Roy

Joshua P Metlay

Theoklis E Zaoutis

Ebbing Lautenbach

Affiliations

Soon will be listed here.

Abstract

Objectives: The prevalence of high-MIC fluoroquinolone-susceptible Escherichia coli (FQSEC) has been increasing. These isolates are one step closer to full fluoroquinolone (FQ) resistance and may lead to delayed response to FQ therapy. Our study aimed to investigate the epidemiology of high-MIC FQSEC in ambulatory urinary tract infections (UTIs).

Patients And Methods: A case-control study was conducted at outpatient services within the University of Pennsylvania Health System, Philadelphia. All female subjects with non-recurrent UTI caused by FQSEC (levofloxacin MIC < 4 mg/L) were enrolled. Cases were subjects with high-MIC FQSEC UTI (levofloxacin MIC >0.12 but < 4 mg/L) and controls were subjects with low-MIC FQSEC UTI (levofloxacin MIC ≤0.12 mg/L). Data on microbiology results and baseline characteristics were extracted from electronic medical records.

Results: During the 3 year study period (May 2008-April 2011), 11 287 episodes of E. coli bacteriuria were identified. The prevalence of FQSEC, FQ-intermediate susceptible E. coli and FQ-resistant E. coli was 75.0%, 0.4% and 24.6%, respectively. A total of 2001 female subjects with FQSEC UTI were enrolled into our study (165 cases and 1836 controls). Independent risk factors for high-MIC FQ susceptibility included Asian race (OR = 2.92; 95% CI = 1.29-6.58; P = 0.02), underlying renal disease (OR = 2.18; 95% CI = 1.15-4.14; P = 0.02) and previous nitrofurantoin exposure (OR = 8.86; 95% CI = 1.95-40.29; P = 0.005).

Conclusions: Asian race, underlying renal disease and previous exposure to nitrofurantoin were identified as independent risk factors for high-MIC FQSEC. There may be some factors that are more common in Asians, which may result in the selection of high-MIC FQSEC. Further studies are necessary to explore these findings.

Citing Articles

Sociodemographic disparities in antibiotic-resistant outpatient urine cultures in a Boston hospital, 2015-2020: a cross-sectional analysis.

Chan C, Westgard L, Romasco A, Gado K, Doron S, Nadimpalli M Int J Equity Health. 2024; 23(1):219.

PMID: 39444033 PMC: 11520160. DOI: 10.1186/s12939-024-02308-y.

Race, ethnicity, and risk for colonization and infection with key bacterial pathogens: a scoping review.

Avendano E, Blackmon S, Nirmala N, Chan C, Morin R, Balaji S medRxiv. 2024; .

PMID: 38712055 PMC: 11071560. DOI: 10.1101/2024.04.24.24306289.

Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care.

Valentine-King M, Hansen M, Zoorob R, Schlueter M, Matas J, Willis S J Antimicrob Chemother. 2024; 79(3):559-563.

PMID: 38217846 PMC: 10904720. DOI: 10.1093/jac/dkae004.

Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection.

Lodise T, Chen L, Wei R, Im T, Contreras R, Bruxvoort K Open Forum Infect Dis. 2023; 10(8):ofad319.

PMID: 37534299 PMC: 10390854. DOI: 10.1093/ofid/ofad319.

Associations between antibiotic prescriptions and recurrent urinary tract infections in female college students.

Rich S, Klann E, Almond C, Larkin E, Nicolette G, Ball J Epidemiol Infect. 2019; 147:e119.

PMID: 30869014 PMC: 6518459. DOI: 10.1017/S0950268818003369.

References

Gales A, Gordon K, Wilke W, Pfaller M, Jones R . Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis. 2000; 36(1):61-4. DOI: 10.1016/s0732-8893(99)00121-2. View

McDonald L, Chen F, Lo H, Yin H, Lu P, Huang C . Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother. 2001; 45(11):3084-91. PMC: 90786. DOI: 10.1128/AAC.45.11.3084-3091.2001. View

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Agarwal R, Gupta D, Ray P, Aggarwal A, Jindal S . Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in North India. J Infect. 2005; 53(2):98-105. DOI: 10.1016/j.jinf.2005.10.021. View

Skiest D, Brown K, Cooper T, Hoffman-Roberts H, Mussa H, Elliott A . Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect. 2006; 54(5):427-34. DOI: 10.1016/j.jinf.2006.09.012. View

Camins B, Farley M, Jernigan J, Ray S, Steinberg J, Blumberg H . A population-based investigation of invasive vancomycin-resistant Enterococcus infection in metropolitan Atlanta, Georgia, and predictors of mortality. Infect Control Hosp Epidemiol. 2007; 28(8):983-91. DOI: 10.1086/518971. View

Gasink L, Fishman N, Nachamkin I, Bilker W, Lautenbach E . Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2007; 28(10):1175-80. DOI: 10.1086/520740. View

Horan T, Andrus M, Dudeck M . CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36(5):309-32. DOI: 10.1016/j.ajic.2008.03.002. View

10.

Hawkey P, Jones A . The changing epidemiology of resistance. J Antimicrob Chemother. 2009; 64 Suppl 1:i3-10. DOI: 10.1093/jac/dkp256. View

11.

Goyal A, Prasad K, Prasad A, Gupta S, Ghoshal U, Ayyagari A . Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res. 2009; 129(6):695-700. View

12.

Lautenbach E, Metlay J, Mao X, Han X, Fishman N, Bilker W . The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis. 2010; 51(3):280-5. PMC: 2897836. DOI: 10.1086/653931. View

13.

Landers T, Apte M, Hyman S, Furuya Y, Glied S, Larson E . A comparison of methods to detect urinary tract infections using electronic data. Jt Comm J Qual Patient Saf. 2010; 36(9):411-7. PMC: 2948408. DOI: 10.1016/s1553-7250(10)36060-0. View

14.

Rattanaumpawan P, Tolomeo P, Bilker W, Fishman N, Lautenbach E . Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect. 2010; 76(4):324-7. PMC: 2962678. DOI: 10.1016/j.jhin.2010.05.023. View

15.

Shaheen B, Boothe D, Oyarzabal O, Wang C, Johnson C . Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats. Am J Vet Res. 2011; 72(1):25-32. DOI: 10.2460/ajvr.72.1.25. View